US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
The unstoppable duo of Emma Stone and Yorgos Lanthimos
CANNES, France (AP) — Before a journalist has even lobbed a question, Emma Stone and Yorgos Lanthimo2024-05-213 Body Problem: Lawyer sentenced to death for Lin Qi murder
By Kelly Ng for the BBCThe headquarter building of the video game developer and publisher of browser2024-05-21South China Sea: US accuses China of 'risky' fighter jet intercepts
Your web browser is no longer supported. To improve your experience update it here2024-05-21'Devastated': Widow pleads for late husband’s dream to be realised
Denise Sturt holds a photo of her late husband Charles, who advocated for the new skatepark which ha2024-05-21Strictly star Giovanni Pernice's former partner Rose Ayling
Giovanni Pernice has been dealt a fresh blow after friend and former Strictly dance partner Rose Ayl2024-05-21Changes to tenancy laws to come into force next year
Housing Minister Chris Bishop expected the measures to increase the supply of rentals. Photo: RNZ /2024-05-21
atest comment